Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 149

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 149
---
 activities. Non-operatingIncome (Expense) Non-operatingincome (expense) consists primarily of interest income on our cash and cash equivalents and marketable securities, interest expense on borrowings under our convertible note agreements, and non-cashchanges in the fair value of our outstanding preferred stock warrant liability and conversion feature derivative liability related to our convertible notes. 99

Results of Operations Comparison of the Years Ended December 31, 2024 and 2023 The following table summarizes our results of operations for the years ended December 31, 2024 and 2023 (in thousands):

|                                                               |     | Year Ended December 31, |    2024 |   |     |   |    2023 |   |     |   |  Change |   |
|:--------------------------------------------------------------|:----|:------------------------|--------:|:--|:----|:--|--------:|:--|:----|:--|--------:|:--|
| Operating expenses                                            |     |                         |         |   |     |   |         |   |     |   |         |   |
| Research and development                                      |     | $                       |  51,171 |   |     | $ |   7,845 |   |     | $ |  43,326 |   |
| General and administrative                                    |     |                         |  13,659 |   |     |   |   3,531 |   |     |   |  10,128 |   |
| Total operating loss                                          |     |                         | (64,830 | ) |     |   | (11,376 | ) |     |   |  53,454 |   |
| Non-operating income (expense)                                |     |                         |         |   |     |   |         |   |     |   |         |   |
| Interest income                                               |     |                         |   1,721 |   |     |   |     811 |   |     |   |     910 |   |
| Interest expense                                              |     |                         |       — |   |     |   |  (4,825 | ) |     |   |   4,825 |   |
| Loss on extinguishment of debt                                |     |                         |       — |   |     |   |  (7,435 | ) |     |   |   7,435 |   |
| Realized gain on sale of